🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — cardiovascular outcomes arm Page 3

Orforglipron ATTAIN-4 — cardiovascular outcomes arm

TrialTracker_MD Mon, May 25, 2026 at 7:53 AM 21 replies 544 viewsPage 3 of 5
Admin
Administrator
2,456
9,812
Oct 2023
Online
May 25, 2026 at 12:08 PM#11

Moderator note: Great discussion, everyone. Just a reminder to keep things civil and evidence-based.

Thread quality is excellent — keep it up. 👍

11 3PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 8 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
May 25, 2026 at 12:25 PM#12

Slightly tangential to Orforglipron ATTAIN-4 but mike_nyc reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

3 19lucas_SP_BR, lisa_labSD, adam_van
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
May 25, 2026 at 12:42 PM#13
AussieAnna said:
Follow-up question: what labs did your doctor order to monitor this

This is exactly right. AussieAnna articulated what I have been trying to explain to my friends for months. The Orforglipron ATTAIN-4 aspect is what made the difference for me.

26 22SkepticalSean, Dr.CardioMD, EndoResFellow and 23 others
Reply Quote Save Share Report
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
May 25, 2026 at 12:59 PM#14

Saving this for reference. Quality thread.

Last edited: May 25, 2026 at 1:59 PM
42 14VendorMark, COA_Karl, MikeFit_NJ and 39 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
May 25, 2026 at 1:16 PM#15

Adding my data to this Orforglipron ATTAIN-4 discussion:

MetricBaselineMonth 4Month 6
Weight260 lbs220 lbs205 lbs
A1C6.4%6.2%5.2%
hsCRP4.03.01.0

Protocol: Tirzepatide 15mg/wk, resistance training 3x/wk, protein 1.2g/kg/day.

5 14RickReta_CO, PharmHunterJen, TomTeleRx and 2 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register